Jeffrey H. Knapp
2017
In 2017, Jeffrey H. Knapp earned a total compensation of $1.7M as Chief Operating Officer at Aimmune Therapeutics, a 49% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $171,000 |
|---|---|
| Option Awards | $1,158,858 |
| Salary | $395,833 |
| Total | $1,725,691 |
Knapp received $1.2M in option awards, accounting for 67% of the total pay in 2017.
Knapp also received $171K in non-equity incentive plan and $395.8K in salary.
Rankings
In 2017, Jeffrey H. Knapp's compensation ranked 6,239th out of 14,666 executives tracked by ExecPay. In other words, Knapp earned more than 57.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,239 out of 14,666 | 58th |
Division Manufacturing | 2,295 out of 5,772 | 60th |
Major group Chemicals And Allied Products | 728 out of 2,075 | 65th |
Industry group Drugs | 564 out of 1,731 | 67th |
Industry Pharmaceutical Preparations | 444 out of 1,333 | 67th |
Source: SEC filing on April 11, 2018.
Knapp's colleagues
We found five more compensation records of executives who worked with Jeffrey H. Knapp at Aimmune Therapeutics in 2017.
2017
Stephen Dilly
Aimmune Therapeutics
Chief Executive Officer
2017
Eric Bjerkholt
Aimmune Therapeutics
Chief Financial Officer
2017
Daniel Adelman
Aimmune Therapeutics
Chief Medical Officer
2017
Douglas Sheehy
Aimmune Therapeutics
General Counsel
2017
Warren DeSouza
Aimmune Therapeutics